Serum protein fingerprint of patients with pancreatic cancer by SELDI technology

IMR OpenIR

	Serum protein fingerprint of patients with pancreatic cancer by SELDI technology
其他题名	Serum protein fingerprint of patients with pancreatic cancer by SELDI technology
	Ma Ning 1; Ge Chunlin 1; Luan Fengming 1; Yao Dianbo 2; Hu Chaojun 2; Li Ning 2; Liu Yongfeng 1
	2008
发表期刊	CHINESE JOURNAL OF CANCER RESEARCH
ISSN	1000-9604
卷号	20 期号:3 页码:171-176
摘要	Objective: To study the serum protein fingerprint of patients with pancreatic cancer and to screen for protein molecules closely related to pancreatic cancer during the onset and progression of the disease using surface-enhanced laser desorption and ionization time of fight mass spectrometry (SELDI-TOF-MS). Methods: Serum samples from 20 pancreatic cancers, 20 healthy volunteers and 18 patients with other pancreatic diseases. WCX magnetic beans and PBSII-C protein chips reader (Ciphergen Biosystems Ins.) were used. The protein fingerprint expression of all the Serum samples and the resulting profiles between cancer and normal were analyzed with Biomarker Wizard system. Results: A group of proteomic peaks were detected. Four differently expressed potential biomarkers were identified with the relative molecular weights of 5705 Da, 4935 Da, 5318 Da and 3243 Da. Among them, two proteins with m/z5705, 5318Da down-regulated, and two proteins with m/z 4935, 3243 Da were up-regulated in pancreatic cancers. Conclusion: SELDI technology can be used to screen significant proteins of differential expression in the serum of pancreatic cancer patients. These different proteins could be specific biomarkers of the patients with pancreatic cancer in the serum and have the potential value of further investigation.
其他摘要	Objective To study the serum protein fingerprint of patients with pancreatic cancer and to screen for protein molecules closely related to pancreatic cancer during the onset and progression of the disease using surface-enhanced laser desorption and ionization time of fight mass spectrometry (SELDI-TOF-MS).Methods Serum samples from 20 pancreatic cancers, 20 healthy volunteers and 18 patients with other pancreatic diseases. WCX magnetic beans and PBSII-C protein chips reader (Ciphergen Biosystems Ins.) were used. The protein fingerprint expression of all the Serum samples and the resulting profiles between cancer and normal were analyzed with Biomarker Wizard system.Results A group of proteomic peaks were detected. Four differently expressed potential biomarkers were identified with the relative molecular weights of 5705 Da, 4935 Da, 5318 Da and 3243 Da. Among them, two proteins with m/z5705, 5318Da down-regulated, and two proteins with m/z 4935, 3243 Da were up-regulated in pancreatic cancers.Conclusion SELDI technology can be used to screen significant proteins of differential expression in the serum of pancreatic cancer patients. These different proteins could be specific biomarkers of the patients with pancreatic cancer in the serum and have the potential value of further investigation.
关键词	PROSTATE-CANCER MASS-SPECTROMETRY PROTEOMIC PATTERNS DIAGNOSIS IDENTIFICATION CARCINOMA EXPRESSION MARKER pancreatic cancer proteomic SELDI biological markers
收录类别	CSCD
语种	英语
资助项目	[Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing]
CSCD记录号	CSCD:3360136
引用统计
文献类型	期刊论文
条目标识符	http://ir.imr.ac.cn/handle/321006/156015
专题	中国科学院金属研究所
作者单位	1.中国科学院金属研究所 2.中国医学科学院 3.Peking Union Med Coll, Beijing 100730, Peoples R China
推荐引用方式 GB/T 7714	Ma Ning,Ge Chunlin,Luan Fengming,et al. Serum protein fingerprint of patients with pancreatic cancer by SELDI technology[J]. CHINESE JOURNAL OF CANCER RESEARCH,2008,20(3):171-176.
APA	Ma Ning.,Ge Chunlin.,Luan Fengming.,Yao Dianbo.,Hu Chaojun.,...&Liu Yongfeng.(2008).Serum protein fingerprint of patients with pancreatic cancer by SELDI technology.CHINESE JOURNAL OF CANCER RESEARCH,20(3),171-176.
MLA	Ma Ning,et al."Serum protein fingerprint of patients with pancreatic cancer by SELDI technology".CHINESE JOURNAL OF CANCER RESEARCH 20.3(2008):171-176.